Compare Endeavour Silver Corp (EXK) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Merck & Co., Inc. — how do they compare? Endeavour Silver Corp trades at $8.65 (market cap $2.54B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 138.3× Endeavour Silver Corp's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Merck & Co., Inc. for 98 Days on average.
| EXK | MRK | |
|---|---|---|
Market Cap | $2.54B | $351.28B |
Volume | 7,077,330 | 7,969,665 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $156.43 |
52-Week Low | $7.07 | $82.49 |
Typical Hold Time | 25 Days | 98 Days |
Enterprise Value | $2.54B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.65, up 3.97% today. The technical outlook is bearish, with moving averages signaling a downtrend, while fundamentals show a transition from a net loss in 2025 to a projected profit in 2026. Recent news highlights operational progress at the Terronera and Kolpa mines, though temporary disruptions occurred. Analyst sentiment is strongly positive, with 78.57% recommending Buy.
The stock presents a growth opportunity driven by mine expansions and favorable silver prices, but faces risks from operational hiccups and high valuation multiples. Investors should weigh the bullish analyst consensus against execution risks and market volatility for silver equities.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
